Search Results - "постинъекционные осложнения"

1

Academic Journal

New etanercept biosimilar — expanding treatment options for immune-mediated inflammatory rheumatic diseases ; Новый биосимиляр этанерцепта - расширение возможностей лечения иммуновоспалительных ревматических заболеваний

Authors: A. E. Karateev, A. M. Lila, А. Е. Каратеев, А. М. Лила

Contributors: The article is sponsored by Sandoz., Статья спонсируется компанией «Сандоз».

Source: Modern Rheumatology Journal; Том 16, № 6 (2022); 92-97 ; Современная ревматология; Том 16, № 6 (2022); 92-97 ; 2310-158X ; 1996-7012

Subject Terms: локальные постинъекционные осложнения, psoriatic arthritis, ankylosing spondylitis, biologic disease-modifying antirheumatic drugs, etanercept, biosimilar, local post-injection complications, псориатический артрит, анкилозирующий спондилит, генно-инженерные биологические препараты, этанерцепт, биосимиляр

File Description: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1377/1318; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2020. 448 с.; Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014 Aug;74(12):1379-410. doi:10.1007/s40265-014-0258-9.; https://www.drugdiscoverytrends.com/50-of-2021s-best-selling-pharmaceuticals/; Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2013 May 31;(5):CD004525. doi:10.1002/14651858.CD004525.pub2.; Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008 Aug 2;372(9636):375-82. doi:10.1016/S0140-6736(08)61000-4. Epub 2008 Jul 16.; Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis. 2010 Jan;69(1):222-5. doi:10.1136/ard.2008.102509.; Ruyssen-Witrand A, Perry R, Watkins C, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020 Feb; 6(1):e001117. doi:10.1136/rmdopen-2019-001117.; Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004 Jul;50(7):2264-72. doi:10.1002/art.20335.; Li ZH, Zhang Y, Wang J, Shi ZJ. Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, doubleblind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol. 2013 Jul;23(5):497-506. doi:10.1007/s00590-012-1035-7. Epub 2012 Jun 29.; Van der Heijde D, Da Silva JC, Douga-dos M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006 Dec;65(12):1572-7. doi:10.1136/ard.2006.056747. Epub 2006 Sep 12.; Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016 Dec;15(sup1):11-34. doi:10.1080/14740338.2016.1240783.; Mehta P, Manson JJ. What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis? Front Immunol. 2020 Apr 7; 11:589. doi:10.3389/fimmu.2020.00589. eCollection 2020.; Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs. 2017 Aug;31(4):299-316. doi:10.1007/s40259-017-0231-8.; Румянцева ОА, Бочкова АГ, Урумова ММ и др. Клинический опыт лечения этанерцептом больных анкилозирующим спондилитом. Научно-практическая ревматология. 2018;56(1):189-95.; Пчелинцева АО, Панасюк ЕЮ, Ряби-цева ОФ и др. Эффективность этанерцепта у больных ревматоидным артритом (результаты российского многоцентрового исследования ЭТАЛОН). Научно-практическая ревматология. 2013;51(6):639-45.; Мазуров ВИ, Лила АМ, Коротаева ТВ. Эрелзи® - биоаналог этанерцепта в лечении ревматических заболеваний и псориаза (резолюция Совета Экспертов). Современная ревматология. 2021;15(4).129-31. doi:10.14412/1996-7012-2021-4-129-131; Deeks ED. GP2015: An Etanercept Biosimilar. BioDrugs. 2017 Dec;31(6):555-8. doi:10.1007/s40259-017-0246-1.; Griffiths CEM, Thaci D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017 Apr;176(4):928-38. doi:10.1111/bjd.15152. Epub 2017 Mar 1.; Gerdes S, Thaci D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):420-7. doi:10.1111/jdv.14605. Epub 2017 Nov 2.; Matucci-Cerinic M, Allanore Y, Kavanaugh A, et al. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open. 2018 Nov 14;4(2):e000757. doi:10.1136/rmdopen-2018-000757. eCollection 2018.; Jaworski J, Matucci-Cerinic M, Schulze-Koops H, et al. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with mode-rate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. Arthritis Res Ther. 2019 May 28;21(1):130. doi:10.1186/s13075-019-1907-x.; Usach I, Martinez R, Festini T, Peris JE. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site. Adv Ther. 2019 Nov; 36(11):2986-96. doi:10.1007/s12325-019-01101-6. Epub 2019 Oct 5.; Ma Z, Liu X, Xu X, et al. Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis. Medicine (Baltimore). 2017 Jun;96(25):e7145. doi:10.1097/MD.0000000000007145.; Bolge SC, Goren A, Tandon N. Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. Patient Prefer Adherence. 2015 Jan 20;9:121-31. doi:10.2147/PPA.S70834. eCollection 2015.; St Clair-Jones A, Prignano F, Goncalves J, et al. Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review. Rheumatol Ther. 2020 Dec;7(4):741-57. doi:10.1007/s40744-020-00245-0. Epub 2020 Nov 18.; Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, doubleblind, parallel-group phase III trial. Ann Rheum Dis. 2017 May;76(5):840-7. doi:10.1136/annrheumdis-2016-210310. Epub 2016 Nov 17.; Cohen S, Samad A, Karis E, et al. Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial. Rheumatol Ther. 2019 Jun;6(2):245-54. doi:10.1007/s40744-019-0152-8. Epub 2019 Mar 27.

Availability: https://mrj.ima-press.net/mrj/article/view/1377

View record from BASE

2

Academic Journal

Постинъекционные осложнения в медицинских организациях, факторы риска и особенности эпидемиологического мониторинга ; Injection complications in medical organizations, risk factors and epidemiological monitoring

Authors: Kozlova, I. I., Ostapenko, N. A., Sisin, E. I., Козлова, И. И., Остапенко, Н. А., Сисин, Е. И.

Source: Вестник Уральского государственного медицинского университета

Subject Terms: POST-INJECTION COMPLICATIONS, INTRAMUSCULAR INJECTIONS, ABSCESS, ПОСТИНЪЕКЦИОННЫЕ ОСЛОЖНЕНИЯ, ВНУТРИМЫШЕЧНЫЕ ИНЪЕКЦИИ, АБСЦЕСС

File Description: application/pdf

Relation: Вестник Уральского государственного медицинского университета. 2018. №3; http://elib.usma.ru/handle/usma/1267

Availability: http://elib.usma.ru/handle/usma/1267

View record from BASE

3

Academic Journal

EPIDEMIOLOGY ASPECTS OF HOSPITAL-ACQUIRED INFECTION MORBIDITY IN HEALTH SURGERY HOSPITALS IN PRIMORSKY REGION ; ЭПИДЕМИОЛОГИЧЕСКИЕ АСПЕКТЫ ЗАБОЛЕВАЕМОСТИ ВНУТРИБОЛЬНИЧНЫМИ ИНФЕКЦИЯМИ В ЛПМО ХИРУРГИЧЕСКОГО ПРОФИЛЯ В ПРИМОРСКОМ КРАЕ

Authors: Martynova A.V., Gorkavaya A.Y., Abashina V.L., Semeikina L.M.

Source: Russian Journal of Infection and Immunity; Vol 7, No 4 (2017); 409-412 ; Инфекция и иммунитет; Vol 7, No 4 (2017); 409-412 ; 2313-7398 ; 2220-7619 ; 10.15789/2220-7619-2017-4

Subject Terms: hospital-acquired infections, injection complications, infections of the urinary tract, purulent-septic infection, nosocomial infection, epidemiology of nosocomial infections, госпитальные инфекции, постинъекционные осложнения, инфекции мочевыводящего тракта, гнойно-септические инфекции, внутрибольничные инфекции, эпидемиология внутрибольничных инфекций